Answers are grounded in this paper and cite their sources.
A collection of rifampin-resistant mutants of Staphylococcus aureus with characterized RNA polymerase beta-subunit (rpoB) gene mutations was cross-screened against a number of other RNA polymerase inhibitors to correlate susceptibility with specific rpoB genotypes. The rpoB mutants were cross-resistant to streptolydigin and sorangicin A. In contrast, thiolutin, holomycin, corallopyronin A, and ripostatin A retained activity against the rpoB mutants. The second group of inhibitors may be of interest as drug development candidates.
No takes yet. Share an insight, caveat, or question.
O’Neill et al. (2000) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: